A patient being treated for sickle cell disease with hydroxyurea (1 g/d) conceived, and drug treatment was discontinued at nine weeks gestational age. The pregnancy and delivery were complicated by vaso-oclusive crises. A healthy male infant was born at 39 weeks with no evidence of congenital malfor
Hydroxyurea therapy for priapism prevention and erectile function recovery in sickle cell disease: a case report and review of the literature
โ Scribed by Anele, Uzoma A.; Kyle Mack, A.; Resar, Linda M. S.; Burnett, Arthur L.
- Book ID
- 125370168
- Publisher
- Springer Netherlands
- Year
- 2014
- Tongue
- English
- Weight
- 152 KB
- Volume
- 46
- Category
- Article
- ISSN
- 0301-1623
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Hematologic malignancy has rarely been reported in adults with sickle cell disease. We describe four sickle cell patients (two with hemoglobin SC, two with hemoglobin SS) who developed hematologic malignancy (acute myeloblastic leukemia, multiple myeloma, malignant histiocytosis, and Hodgkin's disea
Secondary gout is a recognized complication of several hematologic disorders, including many chronic hemolytic anemias characterized by increased purine metabolism. However, gouty arthritis has been described in only a few patients with hemoglobinopathies, and the identification of typical monosodiu